Table 1.
Baseline characteristics and outcomes of 97 responding patients with AML treated with DEC10-VEN
| Characteristic | N (%) or median [IQR] |
|---|---|
| Age, y | 72 [69-78] |
| ≥70 | 67 (69) |
| Male sex | 53 (55) |
| ECOG performance status ≥2 | 22 (23) |
| Peripheral blood blasts, % | 5 [0-24] |
| BM blasts, % | 38 [22-57] |
| Diagnosis | |
| De novo | 50 (52) |
| sAML with AHD | 31 (32) |
| Treatment naive | 12 (12) |
| Previously treated for AHD | 19 (20) |
| Therapy-related | 16 (16) |
| ELN 2017 risk group | |
| Favorable | 26 (27) |
| Intermediate | 16 (16) |
| Adverse | 55 (57) |
| ELN 2017 cytogenetic risk* | |
| Favorable | 0 (0) |
| Intermediate | 57 (59) |
| Adverse | 39 (40) |
| Mutations | |
| NPM1 | 28 (29) |
| FLT3-ITD/TKD | 17 (18) |
| IDH1/2 | 21 (22) |
| TP53 | 23 (24) |
| RUNX1 | 18 (19) |
| ASXL1 | 13 (13) |
| K/NRAS | 20 (21) |
| Prior therapies for AHD | 1 [1-2] |
| Hypomethylating agents | 17 (18) |
| Intensive chemotherapy (IC) | 3 (3) |
| Hypomethylating agents and IC | 2 (2) |
| SCT | 3 (3) |
| Outcomes | |
| CR | 59 (61) |
| CRi | 24 (25) |
| MLFS | 14 (14) |
| MRD negative by flow cytometry | 52 (54) |
| Median time to morphologic response, mo | 1.4 [1.1-2.6] |
| Median no. of cycles to response | 1 [1-2] |
| Median time to negative MRD, mo | 2.0 [0.9-3.1] |
AHD, antecedent hematologic disorder; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; sAML, secondary acute myeloid leukemia.
*
One patient had insufficient metaphases.